Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 2/3 4Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 20OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Advanced Primary Liver Cancer 1

Interventions

fludarabine 2Interleukin-2 2Cyclophosphamide 2toripalimab 1lenvatinib 1epigallocatechin gallate 1avelumab 1Zinc 1Tissue Banks 1Quercetin 1Pemetrexed 1Paclitaxel 1Optical Fibers 1Metformin 1Ethiodized Oil 1Docetaxel 1Dihematoporphyrin Ether 1Cisplatin 1Carboplatin 1Blood Specimen Collection 1Biopsy, Needle 1Bevacizumab 1Albumin-Bound Paclitaxel 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER_GOV × Bevacizumab × Clear all
NCT05411757 2022-06-09

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Shandong Public Health Clinical Center

Phase EARLY_PHASE1 Unknown
12 enrolled

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡